CJC-1295 and Ipamorelin: Identity and Evidence Boundaries

Scope of this reference

This page concerns the catalogue identity of CJC-1295 and Ipamorelin as laboratory materials and the boundaries of what published evidence and batch analysis establish. It is not a treatment guide, a recommendation, a human-use protocol or evidence that either material is safe or effective in people or animals.

Two materials from two different families

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) — a modified version of a GHRH fragment, altered to resist enzymatic degradation.

Ipamorelin is a pentapeptide and a ghrelin-receptor ligand. It is not a GHRH analogue. It acts at a different receptor from CJC-1295, which is a difference of molecular family rather than of degree.

The two are frequently discussed as a unit, which obscures the fact that they are separately listed materials with separate literatures. The listed material is CJC-1295, in the growth hormone collection.

The DAC distinction is the critical identity fact

CJC-1295 appears in the literature and in catalogues in two distinct forms:

• •With DAC — carrying a Drug Affinity Complex modification, which binds to serum albumin and substantially extends how long the molecule persists in circulation in the models studied.
• •Without DAC — sometimes listed under the name *modified GRF (1-29)*, lacking that modification and correspondingly shorter-lived.

These are not interchangeable. They differ in structure, in mass, and in the duration figures reported for them. The catalogue item supplied here is the non-DAC form. Any figure, study or comparison quoted for "CJC-1295" must be checked against which of the two forms it actually concerned, because a great deal of published and secondary material does not say.

Sermorelin, a separate GHRH fragment, is also commonly grouped with these and is a third distinct molecule. The identity distinctions reference sets out how the three differ.

Reading the evidence by tier

• •In-vitro — receptor-binding and cell-based assays. Establishes behaviour in that system only.
• •Animal models — establishes findings in that species under those conditions.
• •Human data — the tier where claims about people could be grounded.

Receptor-level findings are the best-characterised part of this literature, and they are statements about binding in experimental systems. Moving from a receptor interaction to a described physiological result is a step the published record does not support, and it is the step most secondary descriptions of these two materials take without saying so.

What analytical documentation establishes

A certificate of analysis provides evidence about the particular batch tested — its identity, measured composition and purity by the stated method. It does not establish a biological, therapeutic or physiological outcome, and it does not extend to other batches.

Because the DAC and non-DAC forms are distinguishable by mass, the batch report is the document that confirms which form was supplied. Available reports are published in our COA library; the guides to reading a peptide COA and understanding HPLC purity explain what those documents can and cannot show.

Laboratory-use boundary

Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.

We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.